SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending after vehicle deliveries reportedly fell short of market estimates, sparking intense debate. Bulls emphasize the company's record energy storage deployments and future AI/robotics initiatives, while bears point to the continued decline in core vehicle sales as evidence of an overvalued valuation and unmet promises.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing significant volatility and trending due to active debate between bulls and bears regarding its valuation and future prospects. A recent partnership announcement with Surf Air Mobility for its Palantir-powered SurfOS platform is a key catalyst, contributing to positive analyst sentiment around its role in the AI sector. The community is split, with some viewing recent dips as buying opportunities for long-term growth in AI and government contracts, while others point to overvaluation and predict further declines.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is seeing intense trading activity after a recent sharp pullback and subsequent rebound, sparking heated debate among investors. Bulls emphasize the strength of its AI-driven ad tech platform and positive analyst upgrades, highlighting impressive financial performance. Conversely, bears argue the stock is "overvalued" with an unsustainable valuation, pointing to insider selling and an ongoing SEC data-collection inquiry as key risks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing strong upward momentum as the community anticipates a prolonged memory supercycle, driven by robust demand for AI-related High Bandwidth Memory. Analysts are increasingly bullish, with many upgrading price targets and highlighting the company's strong revenue growth and projected margin expansion for the coming year. While many celebrate its significant climb and potential, some caution that the rapid ascent could signal an overheating AI market.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is actively discussed as investors react to recent price dips, driving conversations around its perceived underperformance compared to other major tech stocks. Despite this, many in the community remain highly optimistic, anticipating significant gains in the upcoming year, largely propelled by its powerful AWS cloud services and ongoing advancements in AI. Sentiment indicates the stock is viewed as a "coiled spring" due for a substantial move, even as some debate its valuation and insider selling activity.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is actively trending due to widespread community speculation about an imminent buyout, fueled by significant institutional buying and consistent performance from its Lupkynis franchise. The community is eagerly awaiting clarity on the company's AUR200 pipeline, particularly the previously anticipated Phase 2 indications, amidst ongoing discussions about perceived management communication gaps and the company's strategic direction.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending due to strong anticipation of significant government space and defense contracts, coupled with a recent analyst upgrade and institutional buying. The community is actively discussing the stock's substantial undervaluation and high short interest, fueling speculation about a potential short squeeze. As a critical player in space infrastructure and defense technology, RDW is poised to capitalize on the accelerating commercial and government "space race."

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is actively trending following news of its AI chip unit, Kunlunxin, confidentially filing for a separate Hong Kong IPO, a move the community views as unlocking significant value and bolstering its role in China's domestic AI sector. This development, alongside reports of Deepseek utilizing Baidu Kunlun chips and Apollo Go's expanding global robotaxi initiatives, is fueling investor optimism for Baidu's comprehensive AI capabilities and potential for a substantial market rerating.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending due to its removal from the NASDAQ 100 index and ongoing year-end tax loss harvesting, sparking widespread frustration among investors over its sustained underperformance and competitive headwinds. While many in the community are criticizing the CEO and lamenting significant losses, a counter-narrative suggests the stock is oversold and poised for a potential rebound in the upcoming year, driven by advertising market recovery and election-related spending.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is trending due to widespread anticipation and debate surrounding a potential "game-changer" partnership announcement, expected to significantly boost its federal and sovereign AI ventures. While bulls emphasize its undervalued status, strong financials, and strategic market positioning near key support levels, a vocal segment of the community questions the CEO's credibility over the delayed news and recent volatility. Investors are keenly watching for this catalyst amidst broader small-cap market dynamics, anticipating a potential breakout year for its AI data engineering services.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Should You Sell?

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Time to Sell...

Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?

Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

<ul class="summary-bullets"><li>The list included companies from healthcare, consumer, and banking.</li><li>The stocks were among the most discussed names during the Christmas Eve session.</li><li>Trading took place during a shortened U.S. market session.</li></ul>U.S. stocks finished the shortened Christmas Eve session on a firm footing, with the S&amp;P 500 touching a fresh record as investors leaned into expectations for interest-rate cuts in the year ahead.&nbsp;Optimism was supported by data showing the U.S. economy expanded at its fastest pace in two years during the third quarter, while a drop in new jobless claims on Wednesday pointed to continued resilience in the labor market.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.5% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, gained 0.3%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, rose 0.6%.<h3 class="st-heading-3">Here’s a look at the names that drew the most buzz:</h3><h2 class="st-heading-2">Omeros Corporation (OMER)</h2>Omeros surged 67% in Wednesday’s midday session following its long-awaited&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/omeros-stock-jumps-premarket-after-fda-approves-first-drug-for-rare-transplant-complication/cLesxhYREvL">FDA approval for Yartemlea</a>, the first and only treatment approved for the rare and often-fatal transplant complication TA-TMA. The green light paves the way for a U.S. launch in the first half of next year.<a href="https://stocktwits.com/symbol/OMER">OMER stock</a> is up 69% year-to-date.<h2 class="st-heading-2">Nike (NKE)</h2>Nike climbed 5% in Wednesday’s midday session after a regulatory filing showed board member&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-stock-pops-after-hours-as-apple-s-tim-cook-buys-nearly-3-m-in-shares-amid-turnaround-effort/cLeqcjTREHl">Tim Cook made a nearly $3 million</a> open-market purchase of the stock. The buy stood out as a show of confidence as the company navigates a multi-year turnaround under returning CEO Elliott Hill, even as tariffs and a cautious holiday outlook continue to weigh on sentiment.<a href="https://stocktwits.com/symbol/NKE">NKE stock</a> is up 5% year-to-date.<h2 class="st-heading-2">Citigroup (C)</h2>Citigroup rose 2% in Wednesday’s midday session and extended a powerful rally, pushing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/citi-stock-hits-highest-levels-since-2008-factors-at-play/cLetR7ZREvo">shares to levels last seen since 2008</a>. The stock has logged gains in most recent sessions as investors responded to upbeat brokerage calls, easing regulatory pressure and a sweeping internal overhaul aimed at boosting returns and simplifying the business.C<a href="https://stocktwits.com/symbol/NVO"> stock</a> is up 2% year-to-date.<h2 class="st-heading-2">Dynavax Technologies (DVAX)</h2>Dynavax jumped 38% in Wednesday’s midday session after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">Sanofi agreed to buy the vaccine maker</a> for $2.2 billion in cash. The deal adds Dynavax’s hepatitis B vaccine and pipeline assets to Sanofi’s portfolio and marked one of the day’s clearest takeover-driven moves.<a href="https://stocktwits.com/symbol/DVAX">DVAX stock</a> is up 38% year-to-date.<h2 class="st-heading-2">Agios Pharmaceuticals (AGIO)</h2>Agios rallied 18% in Wednesday’s midday session after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-agio-stock-surge-14-today/cLesxI9REvh">FDA approved Aqvesme</a>, an oral therapy for anemia in adults with alpha- or beta-thalassemia. The approval, backed by late-stage trial data, positions Aqvesme as the only FDA-approved treatment across both transfusion-dependent and non-dependent forms of the disease, with a U.S. launch expected next month.<a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> is up 18% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

With holiday festivities officially beginning in New York with the Thanksgiving Day Parade on Thursday, Santa Claus and elves visited the New York Stock Exchange (NYSE) on November 26, 2025. (Photo by Spencer Platt/Getty Images)

Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

Equity

Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Truist Financial increased their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday...

Here's Why Shares in Agios Pharmaceuticals Popped Today

Key PointsThe new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant...

AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade...

<ul class="summary-bullets"><li>BofA raised AGIO’s price target to $34 from $32, while maintaining a ‘Buy’ rating, according to The Fly.</li><li>The approval is based on results from the global Phase 3 ENERGIZE and ENERGIZE-T trials, which involved 452 patients.</li><li>Agios expects AQVESME to be available in the U.S. by late January 2026.</li></ul>Shares of Agios Pharmaceuticals (AGIO) jumped 14% on Wednesday after the U.S. Food and Drug Administration (FDA) approved its oral therapy for anemia in adults with alpha- or beta-thalassemia, an inherited blood disorder.The FDA approval also prompted BofA to raise AGIO’s price target to $34 from $32, while maintaining a ‘Buy’ rating, according to The Fly. According to the company, AQVESME oral therapy is currently the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent forms of thalassemia.<h2 class="st-heading-2">AQVESME Test Details</h2>The approval is based on results from the global Phase 3 ENERGIZE and ENERGIZE-T trials, which involved 452 patients. Across both studies, AQVESME met all primary and key secondary endpoints, with improvements in hemolytic anemia and quality of life compared with placebo. Patients treated with AQVESME showed significant increases in hemoglobin levels, reduced transfusion burden, and improved fatigue.During the trials, five patients receiving AQVESME experienced adverse reactions suggestive of hepatocellular injury (HCI), with two of them requiring hospitalization. These events occurred within the first six months of treatment and resolved after stopping the drug.To manage this risk, the FDA approved AQVESME with a Risk Evaluation and Mitigation Strategy (REMS) program, which includes regular liver testing. Agios expects AQVESME to be available in the U.S. by late January 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment shifted to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes. AGIO was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/AGIO_png_462a9335f9.webp" alt="AGIO.png">One user sees accumulation but wants higher trading volumes to confirm demand.<stembedurl>https://stocktwits.com/MacroTrackX_1534/message/640057716</stembedurl>Year-to-date, AGIO stock has declined 25%.&nbsp;&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-omeros-stock-surging-fda-verdict-this-week/cLesvbHREv7">Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Agios Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did AGIO Stock Surge 14% Today?

Shares of Agios Pharmaceuticals (AGIO) jumped 14% on Wednesday after the U.S. Food and Drug Administration (FDA) approved its oral therapy for anemia in adults.

Why Did AGIO (Agios Pharmaceuticals) Stock Surge 14% Today?

Agios Pharmaceuticals announced that the FDA approved its oral therapy for anemia in adults with alpha- or beta-thalassemia.

Bank of America Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Bank of America upped their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday...

<ul class="summary-bullets"><li>Retail sentiment turned bullish on SPY, even as Nasdaq-linked QQQ remained under pressure on Stocktwits.</li><li>Investors bracing for low volumes and an early market close, even as fresh GDP data offered a bullish macro backdrop.</li></ul>U.S. stock futures traded cautiously early Wednesday, as markets prepared for a thin, holiday-shortened Christmas Eve session. Tuesday saw a record-setting close, supported by third-quarter GDP data, which was revised upward to a 4.3% annualized growth, significantly higher than the 3.2% consensus.&nbsp;As of 3:20 a.m. ET on Wednesday, Nasdaq 100 futures, S&amp;P 500 futures were flat, while the Dow futures fell 0.1% and the Russell 2000 futures were down 0.2%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, had moved to ‘bullish’ from ‘neutral’ a day ago. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ on Wednesday, amid high message volumes.Trading Holiday Schedule&nbsp;<ul><li>Equities Close: 1:00 PM ET today.</li><li>Bond Markets Close: 2:00 PM ET today.</li><li>Thursday, Dec 25: All U.S. markets are closed for Christmas Day.</li></ul><h2 class="st-heading-2">Trending Stocks To Watch</h2>Alphabet (GOOGL): Waymo said it will update its software used in self-driving vehicles following a high-profile fleet stall in San Francisco. AST SpaceMobile (ASTS): Successfully launched its "BlueBird 6" satellite, the largest commercial communications array ever put into orbit. Also, keep an eye on space-related stocks, such as Starfighters Space Inc. (FJET), which have been in the news this week.&nbsp; Dynavax (DVAX): Shares of Dynavax are in the spotlight following news that pharma giant Sanofi will acquire the vaccine maker to expand its vaccine portfolio in a $2.2 billion deal. Agios Pharmaceuticals Inc. (AGIO): The US FDA has granted approval to the company for AQVESME (mitapivat) for the treatment of anemia in adults who have alpha- or beta-thalassemia. Abivax (ABVX): This stock is catching retail attention amid reports that Eli Lilly met with French officials about a possible M&amp;A deal.&nbsp; Ramaco Resources (METC):&nbsp;In after-hours trading, the board authorized a $100 million stock repurchase program. UiPath (PATH):&nbsp;Gaining traction after S&amp;P Dow Jones Indices announced its admission into the S&amp;P MidCap 400, effective before the year ends. Other noteworthy tickers trending on Stocktwits at the time of writing were Medical Properties Trust (MPW), Critical Metals (CRML) &amp; Churchill Capital X (CCCX).<h2 class="st-heading-2">Other Catalysts To Track</h2>On the economic front, traders&nbsp;will keep an eye out for weekly jobless claims.<ul><li>Initial Jobless Claims (8:30 AM ET)</li><li>EIA Crude Oil Inventories (10:30 AM ET)</li></ul>The light earnings calendar today includes Bright Minds Biosciences (DRUG) and Scully Royalty (SRL).For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 

Is The Stock Market Open On Christmas Eve? US Futures Signal Muted Half-Day For Wall Street

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGIO News

AGIOAgios Pharmaceuticals Inc